Vertex Pharmaceuticals filings document the biotechnology company’s operating results, governance and product-development disclosures. Recent Form 8-K reports include quarterly and annual results releases, selected regulatory and pipeline events involving therapies such as povetacicept, and officer or director transition disclosures.
The company’s proxy materials cover board composition, director nominees, shareholder meeting matters, executive compensation and equity-award information. Vertex filings also provide formal records for disclosure topics tied to its approved medicines, clinical pipeline and governance structure as a Nasdaq-listed operating company.
Vertex Pharmaceuticals director Jennifer Schneider reported routine equity compensation changes. She disposed of 796 shares of common stock back to the company in exchange for 796 deferred stock units under a deferred compensation plan, so this was a non‑market, non‑cash swap rather than a sale.
Schneider also acquired 472 shares of common stock as a grant or award and received 796 deferred stock units, each representing one share of common stock payable upon certain future events. In addition, she was granted stock options for 1,433 shares at an exercise price of $424.45 per share, expiring in 2036, and now directly holds 2,190 shares of Vertex common stock.
Vertex Pharmaceuticals director Bruce I. Sachs reported an acquisition of stock options as compensation. He received a grant of 2,866 stock options for Vertex common stock at an exercise price of $424.45 per share. The options are fully vested and expire on April 30, 2036, and his direct derivative holdings after this grant total 2,866 options.
Vertex Pharmaceuticals director Diana McKenzie reported routine equity compensation and a deferral election involving company stock. She received a grant of 943 shares of common stock at no cost as a restricted stock unit award that will vest based on the grant terms.
Upon vesting of earlier restricted stock units granted on May 1, 2025, she chose to defer 796 shares of common stock into 796 deferred stock units under Vertex’s deferred compensation plan. This is recorded as a disposition of 796 common shares back to the issuer in exchange for an equal number of deferred stock units.
Each deferred stock unit represents one share of common stock and will be paid in stock upon the earliest of her board service ending, a change of control, or her disability or death. After these transactions, she holds 3,174 shares of common stock directly, 7,787.483 deferred stock units, and 207 common shares held indirectly in a trust.
Vertex Pharmaceuticals executive Joy Liu, EVP and Chief Legal Officer, sold 1,104 shares of Vertex common stock in an open-market transaction at $425.02 per share. The sale was made pursuant to a company-approved trading plan under Rule 10b5-1. After this transaction, Liu directly holds 20,729 shares of Vertex common stock.
Vertex Pharmaceuticals director Michel Lagarde received a fully vested stock option grant as part of his compensation. On May 1, 2026, he was awarded options to acquire 2,866 shares of Vertex common stock at an exercise price of $424.45 per share. These options are already fully vested and expire on April 30, 2036, and represent a routine, non‑market transaction rather than an open‑market trade.
Vertex Pharmaceuticals director Alan M. Garber received equity awards as compensation. He was granted 472 shares of Common Stock in the form of restricted stock units that vest, subject to limited exceptions, on the first anniversary of the grant date. He was also granted stock options for 1,433 shares of Common Stock at an exercise price of $424.45 per share, which are fully vested and expire on April 30, 2036. Following the stock grant, he directly holds 7,344 shares of Vertex Common Stock in addition to these options.
Vertex Pharmaceuticals director Lloyd Carney received a fully vested stock option grant covering 2,866 shares of common stock. The option has an exercise price of $424.45 per share and expires on April 30, 2036. Following this award, Carney holds 2,866 stock options directly.
Vertex Pharmaceuticals director Dr. Sangeeta N. Bhatia reported two common stock transactions. She received a grant of 943 shares as a restricted stock unit award that will vest, subject to limited exceptions, on the first anniversary of the grant date. She also completed an open-market sale of 318 shares at $423.73 per share under a company-approved trading plan pursuant to Rule 10b5-1, which was entered into on 05/27/2025. After these transactions, she directly holds 4,924 shares of Vertex common stock.
Vertex Pharmaceuticals delivered strong Q1 2026 results, with total revenues of $2.99 billion, up 8% from Q1 2025. Growth was driven by continued cystic fibrosis (CF) therapies and rapid uptake of newer products ALYFTREK, CASGEVY and JOURNAVX.
Net income rose to $1.03 billion from $646.3 million, and diluted EPS increased to $4.02 from $2.49, helped by the absence of last year’s $379.0 million impairment and much lower acquired in-process R&D. Operating income nearly doubled to $1.14 billion.
R&D spending remained high at $961.6 million, while SG&A climbed 25% to $493.7 million as Vertex invests in launches like JOURNAVX and prepares povetacicept for IgA nephropathy. Cash, cash equivalents and marketable securities increased to $13.0 billion, even after $344.5 million of share repurchases in the quarter.
Vertex Pharmaceuticals reported strong first quarter 2026 results, with total revenue rising 8% to $2.99 billion versus the first quarter of 2025. Growth was driven by cystic fibrosis therapies, especially ALYFTREK, and increasing contributions from CASGEVY and JOURNAVX.
GAAP net income increased to $1.03 billion from $646.3 million, helped by higher product revenues and the absence of last year’s intangible asset impairment charge. Non-GAAP net income rose to $1.15 billion. Vertex ended March 31, 2026 with $13.0 billion in cash, cash equivalents, and marketable securities and reaffirmed full-year 2026 revenue guidance of $12.95–$13.1 billion, including at least $0.5 billion from non-CF products.